Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 54

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 54
---
 estimates
made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits
provide a reasonable basis for our opinion.

  F-1  

  Table of Contents  

Critical audit matters

Critical audit matters are matters
arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to
the audit committee and that: 1) relate to accounts or disclosures that are material to the financial statements and 2) involved especially
challenging, subjective, or complex judgements. We determined that there were no critical audit matters.

We have served as the Group’s auditor since 31
October 2024.

PKF Littlejohn LLP

London, England

Date:

  F-2  

  Table of Contents  

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM

The Board of Directors and Shareholders of Biodexa Pharmaceuticals
plc (formerly known as Midatech Pharma plc)

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated
statements of financial position of Biodexa Pharmaceuticals plc (formerly known as Midatech Pharma plc) and its subsidiaries (the “ Group”)
as of December 31, 2023 and 2022, and the related consolidated statements of comprehensive income, changes in equity, and cash flows for
each of the years in the two-year period ended December 31, 2023, including the related notes (collectively, the “ Consolidated Financial
Statements”). In our opinion, the Consolidated Financial Statements present fairly, in all material respects, the financial position
of the Group as of December 31, 2023 and 2022, and the consolidated results of its operations and its cash flows for each of the year
in the two-year period ended December 31, 2023, in conformity with International Financial Reporting Standards as issued by the International
Accounting Standards Board.

Going Concern Uncertainty

The accompanying Consolidated Financial Statements
have been prepared assuming that the Group will continue as a going concern. As discussed in note 1 to the Consolidated Financial Statements
the Group has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability
to continue as a going concern. Management’s plans regarding these matters are also described in note 1. The Consolidated Financial
Statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These